Daniel Reyner

697 total citations
21 papers, 504 citations indexed

About

Daniel Reyner is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Physiology. According to data from OpenAlex, Daniel Reyner has authored 21 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 5 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Physiology. Recurrent topics in Daniel Reyner's work include Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Diabetes Treatment and Management (5 papers) and Asthma and respiratory diseases (5 papers). Daniel Reyner is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Diabetes Treatment and Management (5 papers) and Asthma and respiratory diseases (5 papers). Daniel Reyner collaborates with scholars based in United States, Sweden and United Kingdom. Daniel Reyner's co-authors include Daniel Wartenberg, Cheryl Siegel Scott, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, Bergur V. Stefánsson, David C. Wheeler, Peter Rossing, Carol A. Pollock and Stefano Del Prato and has published in prestigious journals such as Environmental Health Perspectives, Epidemiology and The Lancet Diabetes & Endocrinology.

In The Last Decade

Daniel Reyner

14 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Reyner United States 7 277 128 124 105 98 21 504
Mira Pavkovic Germany 15 140 0.5× 319 2.5× 69 0.6× 168 1.6× 137 1.4× 23 689
D. Otto United States 8 145 0.5× 65 0.5× 111 0.9× 54 0.5× 56 0.6× 17 473
Kaveh Navab United States 9 63 0.2× 86 0.7× 117 0.9× 99 0.9× 38 0.4× 13 405
Linqiang Ma China 15 298 1.1× 211 1.6× 255 2.1× 28 0.3× 91 0.9× 29 671
Pengcheng Luo China 13 159 0.6× 131 1.0× 63 0.5× 38 0.4× 23 0.2× 27 532
Zihao Zhao China 13 62 0.2× 230 1.8× 34 0.3× 113 1.1× 133 1.4× 40 613
Tingting Wu China 9 112 0.4× 149 1.2× 120 1.0× 34 0.3× 41 0.4× 36 479
Shih-Yi Lin Taiwan 13 105 0.4× 172 1.3× 115 0.9× 65 0.6× 38 0.4× 27 534
Rengin Elsürer Afşar Türkiye 13 66 0.2× 97 0.8× 61 0.5× 19 0.2× 102 1.0× 43 473

Countries citing papers authored by Daniel Reyner

Since Specialization
Citations

This map shows the geographic impact of Daniel Reyner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Reyner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Reyner more than expected).

Fields of papers citing papers by Daniel Reyner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Reyner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Reyner. The network helps show where Daniel Reyner may publish in the future.

Co-authorship network of co-authors of Daniel Reyner

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Reyner. A scholar is included among the top collaborators of Daniel Reyner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Reyner. Daniel Reyner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dransfield, Mark T., Ravi Kalhan, Daniel Reyner, et al.. (2025). Ensifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies. Chronic Respiratory Disease. 22. 4093739194–4093739194. 5 indexed citations
2.
3.
4.
Dransfield, Mark T., Ravi Kalhan, Antonio Anzueto, et al.. (2024). Ensifentrine Added on to LAMA Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD. A6614–A6614. 1 indexed citations
5.
6.
7.
8.
9.
Franssen, Frits M.E., Tara Rheault, Kathleen Rickard, et al.. (2024). Efficacy and safety of ensifentrine in European patients with moderate to severe COPD: pooled results from the ENHANCE trials. PA2995–PA2995.
10.
Mahler, Donald A., Surya P. Bhatt, Tara Rheault, et al.. (2024). Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials. Expert Review of Respiratory Medicine. 18(8). 645–654. 6 indexed citations
11.
Cherney, David Z.I., Gozewijn D. Laverman, Bergur V. Stefánsson, et al.. (2021). Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. Diabetes Obesity and Metabolism. 23(8). 1961–1967. 7 indexed citations
12.
Bailey, Clifford J., Stefano Del Prato, Cheryl Wei, Daniel Reyner, & Gabriela Luporini Saraiva. (2019). Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes Obesity and Metabolism. 21(11). 2564–2569. 9 indexed citations
13.
14.
Pollock, Carol A., David C. Wheeler, Peter Rossing, et al.. (2019). SAT-300 EFFECTS OF DAPAGLIFLOZIN AND DAPAGLIFLOZIN PLUS SAXAGLIPTIN ON HbA1c AND ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: PHASE II/III DELIGHT STUDY. Kidney International Reports. 4(7). S133–S134. 2 indexed citations
15.
Fioretto, Paola, Stefano Del Prato, John B. Buse, et al.. (2018). Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obesity and Metabolism. 20(11). 2532–2540. 136 indexed citations
16.
Wartenberg, Daniel, Daniel Reyner, & Cheryl Siegel Scott. (2001). Errors in TCE Analysis: Response. Environmental Health Perspectives. 109(3). a108–a109. 2 indexed citations
17.
Wartenberg, Daniel & Daniel Reyner. (2000). TCE Meta-Analyses: Wartenberg et al.'s Response.. Environmental Health Perspectives. 108(12). A543–A544. 15 indexed citations
18.
Wartenberg, Daniel, Daniel Reyner, & Cheryl Siegel Scott. (2000). TCE Meta-Analyses: Wartenberg et al.'s Response. Environmental Health Perspectives. 108(12). A543–A543. 1 indexed citations
19.
Wartenberg, Daniel, Daniel Reyner, & Cheryl Siegel Scott. (2000). Trichloroethylene and cancer: epidemiologic evidence.. Environmental Health Perspectives. 108(suppl 2). 161–176. 160 indexed citations
20.
Wartenberg, Daniel, Daniel Reyner, & Cheryl Siegel Scott. (1998). IS TRICHLOROETHYLENE A HUMAN CARCINOGEN. Epidemiology. 9(Supplement). S100–S100.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mira Pavkovic Breakdown of academic impact, for papers by D. Otto Breakdown of academic impact, for papers by Kaveh Navab Breakdown of academic impact, for papers by Linqiang Ma Breakdown of academic impact, for papers by Pengcheng Luo Breakdown of academic impact, for papers by Zihao Zhao Breakdown of academic impact, for papers by Tingting Wu Breakdown of academic impact, for papers by Shih-Yi Lin Breakdown of academic impact, for papers by Rengin Elsürer Afşar
Rankless by CCL
2026